Wave Neuroscience Receives FDA Recognition
FDA Breakthrough Device Designation for adjunctive treatment of Post-Traumatic Stress Disorder (PTSD).
Wave Neuroscience has announced that its innovative Magnetic EEG Resonance Therapy (MeRT) system has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for use as an adjunctive treatment for Post-Traumatic Stress Disorder (PTSD).
“Our team at Wave Neuroscience is honored to receive this designation, which validates our commitment to transforming mental health treatment for those who suffer from PTSD,” said Dr. Leslie S. Prichep, Chief Science Officer of Wave Neuroscience. “Our unique personalized approach to brain health using the MeRT System, offering a non-pharmacological and a non-invasive PTSD treatment option to a broad population suffering from this debilitating, life altering condition. With the FDA’s support, we are accelerating our mission to fill a gap in health care by providing safe and effective treatment of PTSD, as we move forward with our multisite randomized control pivotal study.”
